BioMarin Pharmaceutical Inc

BMRN is in an early Stage 1 basing attempt with a fragile but constructive repair of the 9/21 EMAs and an active Lockout Rally pattern driving medium-term bullish asymmetry. Despite overbought context near prior resistance, price remains accepted above the rising EMAs, confirming continuation bias. Short-term readiness is strong now, supported by a pullback and consolidation into EMAs. Buy Now to participate in the urgency-driven repricing.

• ↑VoxOgo sales grew 20% YoY to $221 M in Q2 and full-year revenues guided to $3.325–3.425 B.
• ↑FDA’s sNDA acceptance for full VoxOgo approval paves way for 2027 market expansion.
• ↓Weak profitability factors signal inefficiency converting revenue into profits amid rising costs.